243 related articles for article (PubMed ID: 27884660)
1. Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes.
Scalzo RL; Moreau KL; Ozemek C; Herlache L; McMillin S; Gilligan S; Huebschmann AG; Bauer TA; Dorosz J; Reusch JE; Regensteiner JG
J Diabetes Complications; 2017 Feb; 31(2):449-455. PubMed ID: 27884660
[TBL] [Abstract][Full Text] [Related]
2. Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.
Chen WJY; Diamant M; de Boer K; Harms HJ; Robbers LFHJ; van Rossum AC; Kramer MHH; Lammertsma AA; Knaapen P
Cardiovasc Diabetol; 2017 May; 16(1):67. PubMed ID: 28526033
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism.
Wang D; Luo P; Wang Y; Li W; Wang C; Sun D; Zhang R; Su T; Ma X; Zeng C; Wang H; Ren J; Cao F
Diabetes; 2013 May; 62(5):1697-708. PubMed ID: 23364453
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
6. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
[TBL] [Abstract][Full Text] [Related]
7. Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus.
Torimoto K; Okada Y; Mori H; Otsuka T; Kawaguchi M; Matsuda M; Kuno F; Sugai K; Sonoda S; Hajime M; Tanaka K; Arao T; Tanaka Y
Cardiovasc Diabetol; 2015 Feb; 14():25. PubMed ID: 25849903
[TBL] [Abstract][Full Text] [Related]
8. [Effects of GLP-1 Agonist Exenatide on Cardiac Diastolic Function and Vascular Endothelial Function in Diabetic Patients].
Wang XH; Han LN; Yu YR; Wang C; Wang B; Wen XR; Huang H; Jing XC
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Jul; 46(4):586-90. PubMed ID: 26480664
[TBL] [Abstract][Full Text] [Related]
9. Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial.
Jørgensen PG; Jensen MT; Mensberg P; Storgaard H; Nyby S; Jensen JS; Knop FK; Vilsbøll T
Diabetes Obes Metab; 2017 Jul; 19(7):1040-1044. PubMed ID: 28188972
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
11. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
[TBL] [Abstract][Full Text] [Related]
12. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.
Nathanson D; Ullman B; Löfström U; Hedman A; Frick M; Sjöholm A; Nyström T
Diabetologia; 2012 Apr; 55(4):926-35. PubMed ID: 22246377
[TBL] [Abstract][Full Text] [Related]
13. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
14. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
Eur J Endocrinol; 2017 Jan; 176(1):77-86. PubMed ID: 27777261
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
16. Exercise capacity in diabetes mellitus is predicted by activity status and cardiac size rather than cardiac function: a case control study.
Roberts TJ; Burns AT; MacIsaac RJ; MacIsaac AI; Prior DL; La Gerche A
Cardiovasc Diabetol; 2018 Mar; 17(1):44. PubMed ID: 29571290
[TBL] [Abstract][Full Text] [Related]
17. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research.
Irace C; De Luca S; Shehaj E; Carallo C; Loprete A; Scavelli F; Gnasso A
Diab Vasc Dis Res; 2013 Jan; 10(1):72-7. PubMed ID: 22732108
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.
Regensteiner JG; Bauer TA; Reusch JE
Diabetes Care; 2005 Dec; 28(12):2877-83. PubMed ID: 16306548
[TBL] [Abstract][Full Text] [Related]
19. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
20. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.
Kelly AS; Bergenstal RM; Gonzalez-Campoy JM; Katz H; Bank AJ
Cardiovasc Diabetol; 2012 Jun; 11():64. PubMed ID: 22681705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
